| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 27 | 2024 | 311 | 5.690 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2023 | 23 | 2.610 |
Why?
|
| Ischemic Attack, Transient | 13 | 2022 | 28 | 2.420 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 8 | 1.620 |
Why?
|
| Fibrinolytic Agents | 7 | 2023 | 44 | 1.500 |
Why?
|
| Hypertension | 5 | 2023 | 524 | 1.420 |
Why?
|
| Brain Ischemia | 8 | 2023 | 37 | 1.340 |
Why?
|
| Telemedicine | 2 | 2020 | 184 | 1.040 |
Why?
|
| Thrombolytic Therapy | 4 | 2017 | 21 | 1.000 |
Why?
|
| Humans | 49 | 2024 | 18430 | 0.940 |
Why?
|
| Diabetes, Gestational | 6 | 2015 | 339 | 0.850 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.830 |
Why?
|
| Mentoring | 1 | 2022 | 28 | 0.800 |
Why?
|
| Female | 31 | 2024 | 13136 | 0.750 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 6 | 0.740 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 6 | 0.730 |
Why?
|
| Hospitals, Community | 1 | 2020 | 23 | 0.730 |
Why?
|
| Middle Aged | 22 | 2024 | 8284 | 0.720 |
Why?
|
| Breast Feeding | 3 | 2015 | 133 | 0.690 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 630 | 0.680 |
Why?
|
| Hospital Mortality | 1 | 2020 | 150 | 0.680 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.680 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.670 |
Why?
|
| Aged | 18 | 2024 | 6417 | 0.670 |
Why?
|
| Aged, 80 and over | 10 | 2022 | 2003 | 0.650 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 208 | 0.640 |
Why?
|
| Male | 20 | 2022 | 10440 | 0.610 |
Why?
|
| Pandemics | 1 | 2020 | 292 | 0.610 |
Why?
|
| Cerebral Angiography | 3 | 2011 | 6 | 0.560 |
Why?
|
| Lactation | 4 | 2014 | 50 | 0.520 |
Why?
|
| Risk Factors | 14 | 2024 | 3449 | 0.520 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 1037 | 0.510 |
Why?
|
| Prospective Studies | 9 | 2024 | 1314 | 0.500 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 172 | 0.500 |
Why?
|
| Hospitalization | 3 | 2021 | 847 | 0.480 |
Why?
|
| Thrombectomy | 2 | 2011 | 2 | 0.480 |
Why?
|
| Endarterectomy, Carotid | 3 | 2022 | 7 | 0.480 |
Why?
|
| California | 8 | 2021 | 2365 | 0.420 |
Why?
|
| Pregnancy | 9 | 2023 | 1516 | 0.420 |
Why?
|
| Life Style | 4 | 2022 | 342 | 0.410 |
Why?
|
| Cohort Studies | 11 | 2020 | 2672 | 0.390 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 567 | 0.390 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 32 | 0.390 |
Why?
|
| Angioplasty | 1 | 2011 | 1 | 0.380 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1296 | 0.360 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 249 | 0.340 |
Why?
|
| Adult | 12 | 2022 | 7910 | 0.340 |
Why?
|
| Heart Failure | 3 | 2024 | 398 | 0.340 |
Why?
|
| Early Diagnosis | 1 | 2009 | 40 | 0.330 |
Why?
|
| Incidence | 5 | 2022 | 1314 | 0.330 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 166 | 0.320 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 1 | 0.310 |
Why?
|
| Lipids | 2 | 2014 | 78 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2015 | 760 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 407 | 0.280 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 554 | 0.280 |
Why?
|
| Primary Prevention | 2 | 2024 | 79 | 0.280 |
Why?
|
| Metabolic Syndrome | 2 | 2014 | 80 | 0.280 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 24 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2023 | 2550 | 0.260 |
Why?
|
| Asymptomatic Diseases | 2 | 2022 | 29 | 0.260 |
Why?
|
| Emergency Treatment | 1 | 2005 | 8 | 0.250 |
Why?
|
| Patient Discharge | 2 | 2020 | 153 | 0.250 |
Why?
|
| Asian Americans | 1 | 2005 | 182 | 0.240 |
Why?
|
| American Heart Association | 1 | 2024 | 50 | 0.240 |
Why?
|
| Angioedema | 1 | 2023 | 7 | 0.230 |
Why?
|
| United States | 11 | 2024 | 4164 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2023 | 310 | 0.230 |
Why?
|
| Physicians, Family | 1 | 2003 | 47 | 0.230 |
Why?
|
| Ticlopidine | 1 | 2013 | 16 | 0.220 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 1 | 0.220 |
Why?
|
| Sex Factors | 3 | 2011 | 661 | 0.220 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 38 | 0.210 |
Why?
|
| Insulin Resistance | 2 | 2014 | 129 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 41 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2024 | 89 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2015 | 60 | 0.200 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 45 | 0.190 |
Why?
|
| Blood Pressure Determination | 2 | 2023 | 58 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2024 | 267 | 0.190 |
Why?
|
| Markov Chains | 3 | 2011 | 24 | 0.190 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 12 | 0.190 |
Why?
|
| Ambulances | 1 | 2020 | 2 | 0.180 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 6 | 0.180 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 8 | 0.180 |
Why?
|
| Angiography | 1 | 2020 | 12 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2020 | 1143 | 0.180 |
Why?
|
| Racism | 1 | 2020 | 22 | 0.180 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.180 |
Why?
|
| Length of Stay | 1 | 2020 | 183 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2011 | 270 | 0.170 |
Why?
|
| Pregnancy in Adolescence | 1 | 2009 | 9 | 0.170 |
Why?
|
| Acute Disease | 2 | 2011 | 144 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 153 | 0.160 |
Why?
|
| Body Height | 1 | 2009 | 62 | 0.160 |
Why?
|
| Decision Trees | 2 | 2011 | 20 | 0.160 |
Why?
|
| Prognosis | 3 | 2016 | 624 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 167 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 476 | 0.160 |
Why?
|
| Registries | 3 | 2011 | 490 | 0.160 |
Why?
|
| Comorbidity | 1 | 2020 | 619 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 211 | 0.150 |
Why?
|
| Time Factors | 3 | 2017 | 1136 | 0.150 |
Why?
|
| Adolescent | 6 | 2016 | 3798 | 0.140 |
Why?
|
| Young Adult | 6 | 2016 | 2518 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 724 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 182 | 0.140 |
Why?
|
| Infant | 4 | 2016 | 1245 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 673 | 0.140 |
Why?
|
| Parity | 3 | 2011 | 74 | 0.130 |
Why?
|
| Age Factors | 2 | 2011 | 965 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 530 | 0.130 |
Why?
|
| Infant Formula | 1 | 2015 | 11 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2020 | 52 | 0.130 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2016 | 254 | 0.130 |
Why?
|
| Obesity | 2 | 2015 | 855 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 52 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 14 | 0.120 |
Why?
|
| Prevalence | 2 | 2011 | 911 | 0.120 |
Why?
|
| Adiponectin | 1 | 2014 | 22 | 0.120 |
Why?
|
| Leptin | 1 | 2014 | 30 | 0.120 |
Why?
|
| Child | 4 | 2016 | 2571 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2007 | 333 | 0.110 |
Why?
|
| Quality of Health Care | 2 | 2020 | 347 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2014 | 53 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 321 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2015 | 872 | 0.110 |
Why?
|
| Intracranial Thrombosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 598 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2005 | 382 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 29 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2012 | 74 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 10 | 0.100 |
Why?
|
| Inpatients | 1 | 2012 | 80 | 0.100 |
Why?
|
| Models, Econometric | 1 | 2011 | 11 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 70 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 375 | 0.090 |
Why?
|
| Gravidity | 2 | 2011 | 8 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 125 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 195 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 743 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 133 | 0.090 |
Why?
|
| Insulin | 2 | 2011 | 208 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 392 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 119 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2011 | 346 | 0.080 |
Why?
|
| Aspirin | 2 | 2013 | 67 | 0.080 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 3 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 17 | 0.080 |
Why?
|
| Ethnic Groups | 1 | 2011 | 501 | 0.080 |
Why?
|
| Waist Circumference | 2 | 2015 | 38 | 0.070 |
Why?
|
| Anthropometry | 2 | 2015 | 67 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2016 | 1478 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 1269 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 187 | 0.070 |
Why?
|
| China | 3 | 2011 | 130 | 0.070 |
Why?
|
| Research Design | 2 | 2015 | 402 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 223 | 0.070 |
Why?
|
| Pacific Islands | 1 | 2005 | 5 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 1360 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 41 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 31 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2005 | 17 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2005 | 253 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 226 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 25 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 185 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 1389 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 32 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 16 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 57 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2003 | 3 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2013 | 165 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2013 | 63 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2003 | 108 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 35 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2023 | 60 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 65 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 17 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 16 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 690 | 0.050 |
Why?
|
| Infant Food | 1 | 2011 | 8 | 0.050 |
Why?
|
| Bottle Feeding | 1 | 2011 | 8 | 0.050 |
Why?
|
| Contraception | 1 | 2011 | 25 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 371 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 106 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 47 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 365 | 0.050 |
Why?
|
| Prejudice | 1 | 2020 | 24 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 18 | 0.050 |
Why?
|
| Self-Management | 1 | 2020 | 30 | 0.050 |
Why?
|
| Risk | 2 | 2011 | 552 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 114 | 0.040 |
Why?
|
| Health Education | 1 | 2020 | 115 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 47 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 91 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2009 | 167 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 193 | 0.040 |
Why?
|
| Educational Status | 1 | 2009 | 205 | 0.040 |
Why?
|
| Probability | 1 | 2009 | 86 | 0.040 |
Why?
|
| Body Composition | 1 | 2009 | 82 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2009 | 185 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 243 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 428 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 320 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2009 | 315 | 0.040 |
Why?
|
| African Americans | 1 | 2020 | 490 | 0.040 |
Why?
|
| Goals | 1 | 2016 | 33 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 77 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 495 | 0.030 |
Why?
|
| Skinfold Thickness | 1 | 2015 | 18 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2009 | 974 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 14 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2014 | 93 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 308 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 271 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 276 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 2 | 0.030 |
Why?
|
| Heparin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 36 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 131 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 150 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 17 | 0.020 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 2011 | 7 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 10 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 15 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 457 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 2 | 0.020 |
Why?
|
| National Health Programs | 1 | 2010 | 10 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 48 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 214 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 83 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 247 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 157 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2010 | 217 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 318 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 494 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 32 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 8 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 13 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 747 | 0.020 |
Why?
|
| Logistic Models | 1 | 2007 | 962 | 0.010 |
Why?
|